We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SAFC Pharma Expands its Pharmorphix Solid State Chemistry Services
News

SAFC Pharma Expands its Pharmorphix Solid State Chemistry Services

SAFC Pharma Expands its Pharmorphix Solid State Chemistry Services
News

SAFC Pharma Expands its Pharmorphix Solid State Chemistry Services

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "SAFC Pharma Expands its Pharmorphix Solid State Chemistry Services"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SAFC®, a member of the Sigma-Aldrich™ Group has announced the second-phase of a $600,000 expansion of its solid-state services Pharmorphix™ research facility in Cambridge, UK, adding 7,500 sq. ft. of laboratory capacity to support growing business within its SAFC Pharma™ focus area.

Solid-form characterization and research enhances understanding and allows modification of the physical properties of active pharmaceutical ingredients (APIs) to ensure patient benefit, optimize product development and protect intellectual property.

As part of a multi-phase development program the additional, fully refitted space is scheduled for completion in the first quarter, 2008 and will augment the current 12,500 sq. ft. facility. The development includes office reorganization and will facilitate installation later this year of additional spectroscopic and diffraction equipment.

SAFC Pharma Vice President of Manufacturing and European Operations, Michael Harris commented, “As new drugs and the regulatory climate continues to become more complex, testing analysis and optimization of APIs plays an increasingly key role in drug development. Through our Pharmorphix solid-state research services SAFC Pharma is a recognized and capable player in this complex field.”

Harris continued, “The additional facilities reinforce our commitment to support customers in niche technologies and is expected to support SAFC business growth from Europe, the US and, increasingly, from Asia Pacific”.

Advertisement